Phase 3 N=185 Patient Narcotic Requirements After Outpatient Otolaryngology Procedures
Outpatient Surgery · Pain, Postoperative
Primary: Narcotic Usage — 4.9; 2.0 Pills
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=32 Safety Follow-up of Treatment With Remestemcel-L in Pediatric Participants Who Have Failed to Respond to Steroid Treatment for Acute GVHD
Grade B Acute Graft Versus Host Disease · Grade C Acute Graft Versus Host Disease · Grade D Acute Graft Versus Host Disease
Primary: Overall Survival Rate Through Day 180 — 68.5 percentage of participants
Phase 2 N=38 A Clinical Study of Efficacy, Safety, Tolerability and PK of ND0612H in Subjects With Advanced Parkinson's Disease
Parkinson's Disease
Primary: Change in Daily "OFF" Time — -2.8; -1.3 Hours
N/A N=14 Sun Protection Factor (SPF) Determination of Two Sunscreen-Containing Lip Balms
Sunscreening Agents
Primary: Arithmetic Mean of Individual Sun Protection Factor (SPFi) Values — 17.3; 17.9; 19.3; 18.4 Ratio
Phase 3 N=307 Study of Pembrolizumab (MK-3475) vs Standard Therapy in Participants With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Carcinoma (MK-3475-177/KEYNOTE-177)
Colorectal Carcinoma
Primary: Progression-Free Survival (PFS) Per RECIST1.1 As Assessed by Central Imaging Vendor — 16.5; 8.2 Months — p=0.0001
Phase 3 N=30 Effect of Omega-3 Fatty Acid on Cortical Function in ADHD
Attention Deficit Disorder
Primary: Attention-Deficit Hyperactivity Disorder Symptom Ratings Using the ADHD Rating Scale (ADHD-RS-IV) — 47.1; 46.1 score on a scale
Phase 1 N=36 Safety, Tolerability, and PK of LBP-EC01 in Patients With Lower Urinary Tract Colonization Caused by E. Coli
Urinary Tract Infections
Primary: Number of Participants With Treatment-related Adverse Events as Assessed by DAIDS v2.1 — 0; 0 Participants
Phase 3 N=336 Evaluation of the Long-term Safety and Tolerability of Metoprolol Versus Nebivolol in Patients With Hypertension
Hypertension
Primary: Change in Average Sitting Diastolic Blood Pressure (DBP) Taken at Trough at the End of Treatment Compared to Baseline — -14.0; -10.9 mm Hg
Phase 2 N=36 Safety and Efficacy Study of AB002 (E-WE Thrombin) in End Stage Renal Disease Patients on Chronic Hemodialysis
End Stage Renal Disease · Thrombosis
Primary: The Number of Subjects With Treatment-emergent Adverse Events (TEAEs) Related to Treatment Will be Summarized Using Frequency Counts (Safety and Tolerability) — 0; 0; 0…
Phase 4 N=50 BPO vs Hibiclens Soap for Surgical Preparation
Propionibacterium Acnes
Primary: Number of Patients With a Positive Propionibacteria Swabs on Day of Surgery After At-Home Washes With Benzoyl Peroxide or Chlorhexidine Gluconate — 25; 24; 14; 11…
Phase 2 N=5 Antioxidant Therapy With N-acetylcysteine for Learning and Motor Behavior in Children With Neurofibromatosis Type 1
Neurofibromatosis 1
Primary: Change From Baseline in Motor Function Measured by Physical and Neurological Examination for Subtle Signs (PANESS) — 0; 3 score on a scale
N/A N=48 Very Low Birth Weight Preterm Infant Bundled Care in the NICU
Preterm Infants
Primary: Mean Heart Rate by Group — 200; 185 beats per minute
Phase 4 N=100 Tranexamic Acid in Surgery of Advanced Ovarian Cancer
Ovarian Cancer
Primary: Perioperative Bleeding Volume — 520; 730 milliliter — p=0.03
N/A N=30 Study of Low Level Laser Therapy to Treat Diabetic Peripheral Neuropathy Foot Pain
Diabetic Peripheral Neuropathy
Primary: Number of Participants With a 30% or Greater Change in Pain Rating on the Visual Analog Scale (VAS) — 18; 4 participants — p=<.0005
N/A N=1,742 Spanish Registry of Cryoballoon Ablation
Atrial Fibrillation
Primary: The Efficacy of the Cryoablation Procedure at 12 Months, Defined as the Absence of Recurrences of Atrial Fibrillation. — 79 percentage of patients freedom from AF